Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
In August 2022, President Biden signed the Inflation Reduction Act (IRA) into law. In this OHE Insight, Amanda Cole explores the expert discussions had at ISPOR US 2023.
A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
19 May 2023
In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours.
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced to deliver the triple win of patient access; healthcare system sustainability; and innovation.
Cell & Gene Therapies: Can We Find Innovative Ways to Pay?
19 April 2023
Join OHE experts in Boston as they provide insights into innovative approaches to reimbursement for cell and gene therapies
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of the antibiotic, regardless of the volume used.
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
During an engaging discussion of Professor Aidan Hollis’ prizewinning proposal with Professor Adrian Towse a range of potential benefits and remaining questions were explored.
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for widespread access.
Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize
25 January 2023
Entrants challenged to devise a globally applicable approach to fair pricing of medicines. Winning entry proposes de-linking the innovation reward payments from the price.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.